NASDAQ · LXRX
Lexicon Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LXRX: Nov 05, 2026
Lexicon Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.04.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.05 | $-0.04 | $-0.07 | 2 |
| Dec 2026 | $-0.04 | $-0.03 | $-0.05 | 2 |
| Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Jun 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · The Motley Fool · MarketBeat · RTTNews- Fintel · Oct 1, 8:43 PM EDTLexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64The average one-year price target for Lexicon Pharmaceuticals (NASDAQCM:LXRX) has been revised to $4.64 / share. This is an increase of 17.91% from the prior estimate of $3.93 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do n
- The Motley Fool · Sep 28, 5:25 PM EDTWhy Lexicon Pharmaceuticals Stock Popped by Almost 6% TodayHe feels it's a clear buy at the current price.
- MarketBeat · Sep 20, 1:01 PM EDTLexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin DataLexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. Speaking at the H.C. Wainwright 28th Annual Global Investment Confer
- RTTNews · Aug 31, 11:39 AM EDTLexicon's Sotagliflozin Shows Consistent Benefit For Heart Failure In Phase 3 Post-Hoc Data(RTTNews) – Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company, on Monday reported new post-hoc results from the Phase 3 SOLOIST-WHF analysis.
- RTTNews · Aug 24, 10:09 PM EDTLexicon Earns Third $10 Mln Milestone Payment From Novo For LX9851(RTTNews) – Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company, on Monday announced that it has gained a third $10 million milestone payment from Novo Nordisk following the achievement of a key Phase 1 patient dosing milestone for LX9851.
- The Motley Fool · Aug 13, 12:15 PM EDTLexicon (LXRX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 6, 5:03 PM EDTLexicon Pharmaceuticals Q2 Earnings Call HighlightsLexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUI
- Zacks · Aug 6, 9:50 AM EDTLexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue EstimatesLexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 7:45 AM EDTRecursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue EstimatesRecursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jun 22, 10:36 AM EDTHere's Why You Should Add LXRX Stock to Your Portfolio NowLexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
- The Motley Fool · Jun 11, 10:05 AM EDTLexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?Lexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs.
- The Motley Fool · Jun 1, 4:40 PM EDTLexicon (LXRX) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Lexicon Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.